ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) Operating Margin
- Operating margin · 12 months: Value -348.32%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -348.32% | Operating income / revenue. Period ending 2026-06-30. $-102.29M ÷ $29.37M × 100 ≈ -348.32% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -102.29M USD | Operating Income (Loss) |
| Revenue | 29.37M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 86.78M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-102.29M | $29.37M | (m) | $86.78M | (m) | -348.32% |
| 2026-03-31 | $-88.36M | $54.71M | (m) | $98.85M | (m) | -161.52% |
| 2025-12-31 | $-76.26M | $82.03M | (m) | $112.21M | (m) | -92.96% |
| 2025-09-30 | $-78.35M | $97.60M | (m) | $131.52M | (m) | -80.27% |
| 2025-06-30 | $-72.57M | $122.12M | (m) | $147.38M | (m) | -59.43% |
| 2025-03-31 | $-82.08M | $143.68M | (m) | $176.48M | (m) | -57.13% |
| 2024-12-31 | $-95.67M | $152.31M | (m) | $195.16M | (m) | -62.81% |
| 2024-09-30 | $-80.55M | $160.40M | (m) | $188.00M | (m) | -50.22% |
| 2024-06-30 | $-89.12M | $163.87M | (m) | $199.94M | (m) | -54.39% |
| 2024-03-31 | $-123.37M | $124.53M | (m) | $193.94M | (m) | -99.07% |
| 2023-12-31 | $-78.20M | $166.80M | (m) | $192.13M | (m) | -46.89% |
| 2023-09-30 | $61.52M | $296.24M | (m) | $182.49M | (m) | 20.77% |
| 2023-06-30 | $44.03M | $264.47M | (m) | $169.10M | (m) | 16.65% |
| 2023-03-31 | $77.31M | $281.04M | (m) | $154.63M | (m) | 27.51% |
| 2022-12-31 | $12.18M | $206.00M | (m) | $147.75M | (m) | 5.91% |
| 2022-09-30 | $-146.92M | $51.50M | (m) | $153.40M | (m) | -285.28% |
| 2022-06-30 | $-163.93M | $40.57M | (m) | $161.11M | (m) | -404.10% |
| 2022-03-31 | $-195.56M | $15.48M | (m) | $168.60M | (m) | -1263.67% |
| 2021-12-31 | $-202.85M | $12.36M | (m) | $173.76M | (m) | -1641.33% |
| 2021-09-30 | $-196.29M | $8.80M | (m) | $165.41M | (m) | -2229.80% |
| 2021-06-30 | $-163.41M | $8.70M | (m) | $137.71M | (m) | -1878.45% |
| 2021-03-31 | $-119.73M | $9.02M | (m) | $99.98M | (m) | -1327.36% |
| 2020-12-31 | $-71.52M | $9.54M | (m) | $57.85M | (m) | -749.81% |
| 2020-09-30 | $-51.26M | $10.27M | (m) | $45.55M | (m) | -499.16% |
| 2020-06-30 | $-37.94M | $11.25M | (m) | $34.91M | (m) | -337.10% |
| 2020-03-31 | $-28.47M | $19.09M | (m) | $34.23M | (m) | -149.16% |
| 2019-12-31 | $-25.51M | $20.79M | (m) | $33.64M | (m) | -122.72% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-21.81M | $15.75M | (m) | $16.98M | (m) | -138.46% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |